{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-090715","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2025-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.819867+00:00","generated_at":"2026-05-17T05:53:19.743035+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"InMed reports FY2025 net loss of $8.2M; BayMedica revenue up 8% to $4.9M","bullets":["Net loss $8.2M vs $7.7M prior year; diluted EPS ($8.36) vs ($20.14) on higher share count.","Cash $11.1M, up from $6.6M; expected to fund operations into Q4 2026.","BayMedica segment sales $4.9M (+8% YoY); gross profit rose to $1.7M from $1.1M.","INM-901 Alzheimer's candidate: significant neuroinflammation reductions and oral bioavailability data.","INM-089 dry AMD program selected intravitreal formulation; doses up to 10x safety margin."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-090715","json":"https://secwatch.observer/filing/0001213900-25-090715.json","markdown":"https://secwatch.observer/filing/0001213900-25-090715.md","text":"https://secwatch.observer/filing/0001213900-25-090715.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000121390025090715/0001213900-25-090715-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000121390025090715/ea0258458-8k_inmed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:53:19.743035+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}